Arvinas heads into the post-earnings week with a split analyst verdict, a stock still trading well below consensus targets, and options positioning that has turned markedly more defensive.
The clearest signal this week came from the Street. Wells Fargo downgraded Arvinas to Equal-Weight from Overweight on August 5, cutting its target to $11 from $15 — a move that reflects growing caution on near-term execution even as the stock closed at $9. That action stands in contrast to BTIG, which reiterated its Buy rating with an $18 target on August 4, and Wedbush, which nudged its Neutral target up to $12 from $11. The overall consensus remains Hold, with four buys against eight holds and a mean target around $14.57 — roughly 62% above the current price. Bulls point to Arvinas's PROTAC platform, the Pfizer and Novartis partnerships on vepdegestrant and ARV-766, and a cash runway into late 2028. Bears flag the gap between pipeline promise and clinical-stage reality, competitive pressure on ARV-806, and a valuation that arguably prices in optimism the data hasn't yet delivered. The price-to-book multiple has drifted up to 3.4x over the past month, even as earnings momentum factor scores rank near the bottom of the universe at 37 and 22 for 30- and 90-day windows respectively.
Options positioning has shifted notably more defensive than recent norms. The put/call ratio reached 0.41 — near its 52-week high of 0.42 and running roughly one standard deviation above its 20-day average of 0.27. That is a sharp pivot from mid-July, when the PCR was running at just 0.13, among the lowest readings of the past year. The move implies a meaningful increase in demand for downside protection since late July, coinciding with the run-up to the earnings report. The stock itself gained nearly 12% on August 4 and is up around 10% on the week to $9.00, recovering from a softer July that left it up just 7% over the trailing month.
Short interest tells a calmer story beneath the surface noise. At 6.4% of the free float, the short position is not trivial, but it has been drifting lower — down roughly 9% from a month ago, when shares short exceeded 4.6 million. The week-on-week change is a marginal 1.3%, and borrow conditions are extremely loose, with availability running at over 5,500% — meaning for every share currently borrowed, there are more than 55 still available in the lending pool. Cost to borrow is just 1.1%, down 21% on the week despite a near-tripling over the past month as the stock moved. There is no squeeze pressure here; the lending market is one of the least constrained in the sector.
On the ownership side, Pfizer Venture Investments holds a 5.4% stake with no reported change since March — a strategic anchor that provides some validation of the platform technology. BlackRock added 188,660 shares through June 30, bringing its position to 10.5% of shares outstanding. Two Sigma built a position meaningfully in Q1, adding 840,000 shares to reach 2.8% of the float, while TCG Crossover trimmed by 279,000 shares over the same period. Insider activity has been uniformly on the sell side across the CEO, CFO, CMO, and CSO through May and June, though the values are modest — the largest single transaction was the CFO's $110,000 sale in May. The one notable exception is Lead Independent Director Briggs Morrison, who bought 20,000 shares at $13.40 in early March — now underwater, but the only insider purchase in the recent record.
The next scheduled earnings event is November 4. Between now and then, the balance of the note is defined by pipeline data flow on ARV-806 and vepdegestrant, and whether the Wells Fargo downgrade represents the beginning of a consensus reset or an isolated call ahead of a catalyst window that bulls still believe can re-rate the stock.
See the live data behind this article on ORTEX.
Open ARVN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
